Skip to content
Screener

Precipio, Inc. PRPO Q3 2026 earnings

Reported November 10, 2026 · After market close

Revenue$7.3MBeat by $5.6M
EPS-$0.00Beat by $2.00
Revenue estimate$1.7M
EPS estimate-$2.00
“In the third quarter we continued to strengthen our financial position, delivering record revenue while maintaining positive Adjusted EBITDA and generating cash from operations. Our pathology business continues to provide a strong operational and financial foundation for growth, while also serving as the clinical development and validation platform for our proprietary diagnostic products. With more than $3.5 million in cash at quarter-end, we believe we are well positioned to accelerate commercialization of our existing product portfolio and pursue the significant longer-term growth opportunities ahead of us.”
Ilan Danieli

Next report

Date not yet announced

FAQ

When did Precipio, Inc. report Q3 2026 earnings?
Precipio, Inc. (PRPO) reported Q3 2026 earnings on November 10, 2026 after market close.
What were Precipio, Inc.'s Q3 2026 revenue and EPS?
Precipio, Inc. reported revenue of $7.3M and eps of $-0.00 for Q3 2026.
Did Precipio, Inc. beat estimates in Q3 2026?
Revenue beat the consensus estimate of $1.7M by $5.6M. EPS beat the consensus estimate of $-2.00 by $2.00.
How did Precipio, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 18.4% from $6.2M a year earlier and eps grew 91.0% from $-0.05.
Where can I find Precipio, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-125196) and the 10-Q periodic report (0001104659-26-125241) directly on SEC EDGAR. The filing index links above go to sec.gov.